Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.25), $0.01 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $19 million versus the consensus estimate of $23.65 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.